Journal of Nephrology

Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes

By Irene Capelli, Daniele Vetrano, Danilo Ribichini, Giuseppe Cianciolo

Cohort study of 132 peopleInterventions

12 months

The paper

Irene Capelli, Daniele Vetrano, Danilo Ribichini, Giuseppe Cianciolo

IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

Journal of Nephrology, 12 Aug 2026

doi.org/10.1093/joneph/aajag105 PubMed 42592709

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Frontiers in Endocrinology4 Oct 2026
Underweight is linked to higher kidney disease risk in diabetes